Impact of phase 3 PlanB trial on evidence-based breast cancer management in clinical practice

Impact of phase 3 PlanB trial on evidence-based breast cancer management in clinical practice

EMJ

3 years
933 Views
Share
Want to watch this again later?
Sign in to add this video to a playlist. Login
0 0
Category:
Description:
At the 10th European Breast Cancer Conference (EBCC), held in Amsterdam, the Netherlands, from 9 to 11 March 2016, Oleg Gluz, MD, from the West German Study Group, Mönchengladbach, Germany, discusses the impact of the outcomes from PlanB on adjuvant decision-making for patients with early breast cancer. PlanB is a prospective phase 3 trial evaluating the Oncotype DX® 21-gene Recurrence Score® result for defining a low-risk subgroup of patients with node-negative disease and high-risk clinicopathological factors as well as patients with node-positive disease who could be treated with adjuvant endocrine therapy alone. This content is supported by Genomic Health, Inc. European Medical Journal Website: http://emjreviews.com/ Twitter: https://twitter.com/EMJReviews Facebook: https://www.facebook.com/emjreviews
Up Next Autoplay
Translating genomics to precision medicine for breast cancer care: Ongoing clinical studies
Translating genomics to precision medicine for breast cancer care: Ongoing clinical studies
Category: Acute Lymphoblastic Leukemia
869 Views
EMJ 3 years
Translating genomics to precision medicine for breast cancer care: Ongoing clinical studies
Translating genomics to precision medicine for breast cancer care: Ongoing clinical studies
Category: Acute Lymphoblastic Leukemia
2 Views
EMJ 3 years
Translating genomics to precision medicine for breast cancer care: Ongoing clinical studies
Translating genomics to precision medicine for breast cancer care: Ongoing clinical studies
Category: Acute Lymphoblastic Leukemia
6 Views
EMJ 3 years
Identifying breast cancer patients who can be spared chemotherapy, evidence from recent studies
Identifying breast cancer patients who can be spared chemotherapy, evidence from recent studies
Category: Acute Lymphoblastic Leukemia
595 Views
EMJ 3 years
5-year outcomes from PlanB: Phase 3 trial evaluating the Oncotype DX® Breast Cancer Assay in node-positive and high-risk node-negative breast cancer
5-year outcomes from PlanB: Phase 3 trial evaluating the Oncotype DX® Breast Cancer Assay in node-positive and high-risk node-negative breast cancer
Category: Acute Lymphoblastic Leukemia
539 Views
EMJ 3 years
Overview of prospective phase 3 PlanB trial of 21-gene Recurrence Score® result in breast cancer
Overview of prospective phase 3 PlanB trial of 21-gene Recurrence Score® result in breast cancer
Category: Acute Lymphoblastic Leukemia
594 Views
EMJ 3 years
Addressing inequalities and unmet needs in breast cancer patients
Addressing inequalities and unmet needs in breast cancer patients
Category: Acute Lymphoblastic Leukemia
500 Views
EMJ 3 years
Breast cancer in Europe: Epidemiology and improving outcomes
Breast cancer in Europe: Epidemiology and improving outcomes
Category: Acute Lymphoblastic Leukemia
431 Views
EMJ 3 years
2005–2015 global analysis of advanced breast cancer
2005–2015 global analysis of advanced breast cancer
Category: Acute Lymphoblastic Leukemia
517 Views
EMJ 3 years